Quantcast

Latest Soligenix Inc. Stories

2014-09-23 08:29:51

PRINCETON, N.J., Sept. 23, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has appointed Rasappa Arumugham, PhD, as its Vice President of Biopharmaceutical Development. Dr. Arumugham has over 25 years of diverse experience in biopharmaceutical research and development (R&D) in the...

2014-09-19 08:25:40

PRINCETON, N.J., Sept. 19, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (NIH) (specifically funded by the National Institute...

2014-09-17 08:28:52

Pivotal Phase 3 Clinical Trial Targeted to Begin in First Half of 2015 PRINCETON, N.J., Sept. 17, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that agreement has been reached with the US Food and Drug Administration (FDA) on the design of a pivotal, Phase 3 clinical trial evaluating its...

2014-09-09 08:30:50

New patent includes composition of matter claims PRINCETON, N.J., Sept. 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the US Patent and Trademark Office (US PTO) granted patent 8,808,710 entitled "Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine...

2014-09-08 08:29:28

Presentation to be Webcast Live, 1:15 PM EDT, September 9th PRINCETON, N.J., Sept. 8, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 16(th) Annual Rodman & Renshaw Global...

2014-09-05 08:23:11

Newly Acquired SGX301 Orphan Drug Candidate Being Evaluated for Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J., Sept. 5, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin). SGX301 is poised to enter...

2014-09-02 08:29:01

All vaccinated animals exposed to a lethal aerosol of ricin toxin survive PRINCETON, N.J., Sept. 2, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin...

2014-08-11 08:28:46

PRINCETON, N.J., Aug. 11, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the second quarter and six months ended June 30, 2014. Soligenix's revenues for the quarter and six months ended June 30,...

2014-08-01 08:26:07

Awarded $2.1 million in additional funding PRINCETON, N.J., Aug. 1, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to...

2014-07-09 08:20:35

Milestone Achieved under $9.4 Million NIAID Cooperative Grant PRINCETON, N.J., July 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the combination of RiVax(TM) and VeloThrax(TM) induces protective immunity to...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related